| Dossier: | Ctd |
|---|---|
| Transport Package: | Free |
| Specification: | 0.2mg |
| Trademark: | Sinolead |
| Origin: | China |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier | Generic Name | Voglibose Tablets 0.2mg |
| Strength | 0.2mg |
| Packing | 10tabs/blister,3blisters/box |
| Origin | China |
This product is white or yellowish.
Improve diabetic postprandial hyperglycemia. (This product is suitable for patients receiving diet therapy, exercise therapy did not get significant effect, or patients in addition to diet therapy, exercise therapy also take oral hypoglycemic drugs or insulin preparations did not get significant effect.)
Matters needing attention:
1. The following patients should be treated with caution
1) Patients who are taking other diabetes medications (taking this product at the same time may cause hypoglycemia).
2) Patients with a history of abdominal surgery or intestinal obstruction (because taking this product may increase intestinal gas, prone to intestinal obstruction-like symptoms)
3) Patients with chronic intestinal diseases accompanied by digestive and absorption disorders (due to the possibility of adverse reactions of the digestive tract, it is possible to worsen the condition).
4) Patients with Roem-held syndrome, severe hernia, large intestine stenosis and ulcers. (Because taking this product may increase intestinal gas, it may worsen the condition.)
5) Patients with severe liver dysfunction (changes in metabolic status may induce significant changes in glycemic control, and in cases of severe cirrhosis, hyperammonemia may worsen with impaired consciousness).
6) Patients with severe renal dysfunction (changes in metabolic status may induce significant changes in glycemic control).
2. Important note
1) This product is only used for patients who have been clearly diagnosed with diabetes, and it must be noted that in addition to diabetes, abnormal glucose tolerance and positive urine sugar may also appear diabetes-like symptoms (renal glycosuria, senile glucose metabolism abnormalities, thyroid function abnormalities, etc.).
2) For patients who only receive basic diabetes treatment, namely diet therapy and exercise therapy, the blood glucose level is limited to 200mg/dl(11.1mmol/L) or above 2 hours after meals.
3) In addition to diet therapy and exercise therapy, for patients taking oral hypoglycemic agents or insulin preparations, the index of taking this product is that the fasting blood glucose value is above 140 mg/dl(7.8mmol/L).
4) During the administration of this drug, it is necessary to regularly monitor the blood sugar value and pay attention to observation, and fully pay attention to the necessity of continuous medication. If the effect of controlling postprandial blood glucose is not satisfactory after 2 to 3 months of medication (the blood glucose value of intravenous plasma 2 hours after a meal cannot be controlled below 200mg/dl(11.1mmol/L)), other more appropriate treatment methods must be considered.
In addition, when the postprandial blood glucose is fully controlled (the blood glucose value of the intravenous plasma drops below 160 mg/dl(8.9mmol/L) 2 hours after lunch), diet therapy, exercise therapy, or oral hypoglycemic agents or insulin preparations can fully control the blood glucose, you should stop taking this product and pay attention to observation.
5) When using this product, patients should be fully explained the symptoms of hypoglycemia and its treatment.
6) Drug delivery: Drugs packaged in aluminum-plastic blister should be taken out of the aluminum-plastic blister sheet (it has been reported that due to the misuse of the aluminum-plastic blister sheet, the hard acute Angle pierced the esophageal mucosa, and then perforated, complicated with mediastinitis and other serious complications).
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}